FY2026 Earnings Estimate for CAPR Issued By Roth Capital

Capricor Therapeutics Inc (NASDAQ:CAPR) – Investment analysts at Roth Capital issued their FY2026 earnings per share (EPS) estimates for shares of Capricor Therapeutics in a report issued on Tuesday, May 20th. Roth Capital analyst B. Pachaiyappan expects that the biotechnology company will post earnings of ($0.72) per share for the year. Roth Capital currently has a “Buy” rating and a $31.00 target price on the stock. The consensus estimate for Capricor Therapeutics’ current full-year earnings is ($1.21) per share.

Capricor Therapeutics (NASDAQ:CAPR) last issued its earnings results on Tuesday, May 13th. The biotechnology company reported ($0.53) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.33) by ($0.20). The business had revenue of $2.73 million during the quarter, compared to the consensus estimate of $3.16 million. Capricor Therapeutics had a negative return on equity of 112.95% and a negative net margin of 146.86%. During the same quarter in the previous year, the firm posted ($0.31) earnings per share.

Other research analysts have also issued reports about the stock. Cantor Fitzgerald reissued an “overweight” rating and set a $30.00 target price on shares of Capricor Therapeutics in a research note on Wednesday, May 14th. HC Wainwright reiterated a “buy” rating and set a $77.00 price objective on shares of Capricor Therapeutics in a report on Monday, March 17th. Six investment analysts have rated the stock with a buy rating, According to MarketBeat, the company presently has an average rating of “Buy” and an average target price of $35.50.

Capricor Therapeutics Stock Up 6.2%

NASDAQ:CAPR opened at $11.01 on Wednesday. The company has a fifty day moving average of $10.61 and a 200-day moving average of $13.59. The firm has a market capitalization of $502.90 million, a P/E ratio of -10.39 and a beta of 0.85. Capricor Therapeutics has a twelve month low of $3.52 and a twelve month high of $23.40.

Hedge Funds Weigh In On Capricor Therapeutics

A number of large investors have recently modified their holdings of CAPR. Charles Schwab Investment Management Inc. increased its stake in Capricor Therapeutics by 51.5% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 111,336 shares of the biotechnology company’s stock valued at $1,536,000 after purchasing an additional 37,868 shares in the last quarter. Magnus Financial Group LLC acquired a new position in shares of Capricor Therapeutics during the fourth quarter valued at about $276,000. Swiss National Bank bought a new stake in shares of Capricor Therapeutics during the fourth quarter worth about $930,000. JPMorgan Chase & Co. increased its position in shares of Capricor Therapeutics by 419.5% during the third quarter. JPMorgan Chase & Co. now owns 56,199 shares of the biotechnology company’s stock worth $855,000 after acquiring an additional 45,381 shares in the last quarter. Finally, Alliancebernstein L.P. acquired a new stake in shares of Capricor Therapeutics in the 4th quarter worth about $183,000. 21.68% of the stock is currently owned by institutional investors.

About Capricor Therapeutics

Capricor Therapeutics, Inc (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.